Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (NASDAQ: TMDX) has announced a strategic collaboration with Mercedes-Benz to establish Italy's first dedicated organ transplantation ground transportation network. The initiative will deploy specially equipped Mercedes-Benz V-Class vehicles across four National OCS Program (NOP) hubs in Milan, Rome, Padua, and Bari.
The network will support TransMedics' Organ Care System (OCS) perfusion technology and will be operational by the end of 2025. Each hub will be equipped with OCS Lung, Heart, and Liver Systems and staffed with clinical perfusionists, providing 24/7 support to transplant centers. The Italian National Command Center will be based in Santa Giulia, Milan.
This collaboration marks TransMedics' first step in replicating its successful U.S. NOP model in Europe, potentially laying the groundwork for a broader European transplant logistics network.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two upcoming investor conferences in New York this September.
Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 10:00 a.m. EST, followed by a presentation at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 12:15 p.m. EST. Both presentations will be available via webcast on the company's investor relations website.
TransMedics (Nasdaq: TMDX) has received FDA conditional IDE approval to initiate its Next-Generation OCS ENHANCE Heart trial. The trial consists of two parts: Part A will evaluate prolonged heart perfusion using OCS™ Heart System, while Part B aims to demonstrate superiority of OCS Heart perfusion in donation after brain death (DBD) cases compared to static cold storage methods.
The groundbreaking trial is expected to include over 650 patients, potentially making it the largest heart preservation for transplant trial worldwide. The company plans to initiate both the ENHANCE Heart and DENOVO Lung trials in Q4 2025, with expectations for these trials to drive clinical adoption throughout 2026 and beyond.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has granted equity incentives to 14 new employees as employment inducements. The compensation package includes 21,458 non-qualified stock options with an exercise price of $105.24 per share and 14,283 restricted stock units (RSUs).
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group, Inc. Inducement Plan.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, reported strong Q2 2025 financial results. The company achieved revenue of $157.4 million, marking a 38% increase year-over-year, and generated net income of $34.9 million ($0.92 per diluted share).
Key highlights include receiving conditional IDE approval for the Next-Gen OCS™ Lung trial, launching the NOP ACCESS™ digital ecosystem, and maintaining a strong 61% gross margin. The company has raised its full-year 2025 revenue guidance to $585-605 million, representing 35% growth at the midpoint compared to the previous guidance of $565-585 million.
TransMedics maintains a robust financial position with $400.6 million in cash as of June 30, 2025, and remains focused on achieving its target of 10,000 US NOP transplants by 2028.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy solutions, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 11:30 a.m. ET at the InterContinental Boston Hotel.
Investors can access both the live and archived webcast of the fireside chat, along with the company's standard investor presentation, through the "Investors" section of TransMedics' website at investors.transmedics.com.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its Second Quarter 2025 financial results announcement for July 30, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can join via phone using specific dial-in numbers or access the webcast through TransMedics' investor relations website.
TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.